Cytogenetic Systems Market Snapshot (2022-2032)

[285 Pages Report] Global cytogenetic systems demand is anticipated to be valued at US$ 1,688.5 Million in 2022, forecast to grow at a CAGR of 11.0% to be valued at US$ 5,327.8 Million from 2022 to 2032. Growth is attributed to the increase in incidence of genetic disorders and cancer.

Report Attribute Details
Growth Rate (2016 to 2021) 8.5% CAGR
Expected Market Value (2022) US$ 1,688.5 Million
Anticipated Forecast Value (2032) US$ 5,327.8 Million
Projected Growth Rate (2022 to 2032) 11.0% CAGR

Cytogenetics is a branch of genetics dealing with the study of number and structure of human and animal chromosomes. It offers various applications in terms of diagnosis and treatment of diseases such as cancer and genetic disorders such as Down syndrome and Cri du Chat syndrome. Cytogenetic systems are the equipment designed to carry out cytogenetic analyses.

It can help detect risk of common aneuploidies (phenomenon of having extra or missing chromosomes) and syndromes due to chromosomal structural abnormalities. Diagnosis and treatment of many leukemia, lymphomas, and solid tumors depends on cytogenetic analysis of specific chromosomal anomalies.

The Increasing incidence of cancer and related growth in mortality per year are the major factors that are expected to boost the growth of the cytogenetic systems market during the forecast period.

On the other hand, high cost of cytogenetic instruments is one of the major factors that is expected to hamper the growth of Cytogenetic Systems market over the analysis period.

Don't pay for what you don't need

Customize your report by selecting specific countries or regions and save 30%!

Which are Some Prominent Drivers Spearheading Cytogenetic Systems Market Growth?

The rising demand of early diagnosis of severe life-threatening diseases such as cancer and diagnosis of disorders due to chromosomal anomalies in developing embryos, is one of the major factors that is expected to augment the growth of the Cytogenetic Systems market over the analysis period.

In addition, expansion of geriatric population pool, rising exposure to dangerous chemicals and ultraviolet rays, increase in numbers of people adopting bad habits such as smoking and drinking and the sedentary lifestyle are some other factors that are anticipated to accelerate the growth of the market in the near future.

The growth of the global cytogenetics market is majorly driven by increase in incidence of genetic disorders and cancer. Other factors boosting the market growth include increase in focus on targeted cancer treatment, rise in aging population, and increase in prevalence of chronic diseases. Conversely, transition from fluorescence in situ hybridization to array based is expected to provide lucrative growth opportunities for the global market.

What are the Challenges Faced by the Cytogenetic Systems Industry?

There are some factors which are expected to impede the growth of the Cytogenetic Systems market over the analysis period, such as technical limitations and complexities associated with the equipment.

However, high cost of cytogenetic instruments, and lack of awareness about advanced technological methodologies, especially in low and middle income countries and high cost of sophisticated devices are also expected to hinder the market growth during the forecast period.

Sabyasachi Ghosh
Sabyasachi Ghosh

Principal Consultant

Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Why is North America Emerging as an Opportunistic Cytogenetic Systems Market?

In terms of regional platform, North America holds a significant market share in Cytogenetic Systems market. The region is expected to surge at over 42.1% share from 2022 to 2032.

North America is expected to witness promising growth, attributed to rising awareness about molecular cytogenetics, growing number of diagnostic laboratories and research institutions focused on cytogenetics in the region.

How is Europe Contributing to Growth of the Cytogenetic Systems Market?

According to Future Market Insights, Europe is expected to provide immense growth opportunities for Cytogenetic Systems, and is expected to reach at a highest share of 27.3% in 2022.

Europe is expected to witness the largest market growth, owing to the presence of a huge population in need, high birth rate, rising caseload of pre and postnatal disorders, and increasing number of cases of different types of cancer.

Get the data you need at a Fraction of the cost

Personalize your report by choosing insights you need
and save 40%!

Role of Start-ups in Cytogenetic Systems Market

There are many prominent market players in the cytogenetic systems market, working hand-in-hand to provide the best-in-class cytogenetic systems for enhancing the global cytogenetic arena. However, there are many global start-ups in the cytogenetic systems market, who are stepping forward in matching the requirements of the cytogenetic systems domain.

Global Startups of Cytogenetic Systems Market:

  • Helix
  • BillionToOne
  • Genapsys
  • Color
  • Prenetics
  • Sophia Genetics
  • Embark
  • Gero
  • Insilico Medicine
  • Medgenome

Market Competition

Some of the key participants present in the global Cytogenetic Systems market include ADS Biotec Inc., Genial Genetics, Laboratory Imaging s.r.o., MetaSystems, Agilent Technologies, Cytocell Ltd, Leica Biosystems Nussloch GmbH, Applied Spectral Imaging, Irvine Scientifi­c, PerkinElmer Inc., Bio-Rad Laboratories, Inc. and Abbott Laboratories, among others.

Attributed to the presence of such high number of participants, the market is highly competitive. While global players such as ADS Biotec Inc., Genial Genetics, Laboratory Imaging s.r.o., and MetaSystems account for a considerable market size, several regional level players are also operating across key growth regions, particularly in North America.

Recent Developments

  • In March 2022, Genial, a leading software provider to healthcare and life sciences and Cirdan, a global leader in laboratory information systems, announced a partnership to offer a LIS solution covering all disciplines, including genetics, to healthcare customers across the globe. The partnership was formed due to the increasing need for laboratories to replace legacy laboratory systems across all disciplines, including Genetics. Combining the Genial iGene system with the Cirdan ULTRA LIS will enable both parties to offer a complete LIS solution, which is well integrated and highly efficient, in a very timely manner.
  • In April 2021, Applied Spectral Imaging (ASI) and KromaTiD, Inc. entered into a strategic commercial partnership, granting ASI worldwide rights to market KromaTiD’s proprietary Pinpoint FISH™ (PPF) probes and assay services. PPF is used by researchers around the world to directly analyze unique and small genomic targets in tissues, microarrays, and dissociated cells. KromaTiD currently provides commercial dGH™ and PPF products and services to industry, institutional and academic researchers assessing the integrity of engineered cells, as well as researchers visualizing novel genomic structural variants in oncology and undiagnosed genetic diseases.

Report Scope

Report Attribute Details
Growth Rate CAGR of 11.0% from 2022 to 2032
Market Value in 2022 US$ 1,688.5 Million
Market Value in 2032 US$ 5,327.8 Million
Base Year for Estimation 2021
Historical Data 2016 to 2021
Forecast Period 2022 to 2032
Quantitative Units Revenue in US$ Million and CAGR from 2022 to 2032
Report Coverage Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends and Pricing Analysis
Segments Covered
  • Technology
  • Application
  • End User
  • Region
Regions Covered
  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East & Africa
Key Countries Profiled
  • USA
  • Canada
  • Brazil
  • Mexico
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • China
  • Japan
  • South Korea
  • GCC
  • South Africa
  • Israel
Key Companies Profiled
Customization Available Upon Request

Key Segments Profiled in the Cytogenetic Systems Industry Survey

Cytogenetic Systems Market by Technology:

  • Flow Cytometry-based Cytogenic Systems
  • Fluorescence In Situ Hybridization (FISH) based Cytogenic Systems
  • Multiplex- Fluorescence In Situ Hybridization (M-FISH) based Cytogenic Systems
  • Comparative Genomic Hybridization (CGH) based Cytogenic Systems

Cytogenetic Systems Market by Application:

  • Cytogenetic Systems for Genetic Disorders
  • Cytogenetic Systems for Neoplastic Diseases
  • Cytogenetic Systems for Personalized Medicine
  • Cytogenetic Systems for Other Applications

Cytogenetic Systems Market by End Users:

  • Cytogenetic Systems for Hospitals
  • Cytogenetic Systems for Clinics
  • Cytogenetic Systems for Diagnostic Laboratory Centers
  • Cytogenetic Systems for Research Institutes

Cytogenetic Systems Market by Region:

  • North AmericaCytogenetic Systems Market
  • Latin AmericaCytogenetic Systems Market
  • EuropeCytogenetic Systems Market
  • Asia Pacific Cytogenetic Systems Market
  • Middle East & AfricaCytogenetic Systems Market

Frequently Asked Questions

What is the anticipated growth of the cytogenetic systems market until 2032?

FMI projects the global cytogenetic systems market to expand at an 11.0% value CAGR by 2032

Which region is forecast to be the most lucrative for cytogenetic systems market growth?

North America is expected to be the most opportunistic Cytogenetic Systems market, accumulating a 42.1% revenue share

Which are some prominent Cytogenetic Systems manufacturers?

ADS Biotec Inc., Genial Genetics, Laboratory Imaging s.r.o., and MetaSystems are some prominent Cytogenetic Systems manufacturers

Table of Content

1. Executive Summary

    1.1. Global Market Outlook

    1.2. Demand-side Trends

    1.3. Supply-side Trends

    1.4. Technology Roadmap Analysis

    1.5. Analysis and Recommendations

2. Market Overview

    2.1. Market Coverage / Taxonomy

    2.2. Market Definition / Scope / Limitations

3. Market Background

    3.1. Market Dynamics

        3.1.1. Drivers

        3.1.2. Restraints

        3.1.3. Opportunity

        3.1.4. Trends

    3.2. Scenario Forecast

        3.2.1. Demand in Optimistic Scenario

        3.2.2. Demand in Likely Scenario

        3.2.3. Demand in Conservative Scenario

    3.3. Opportunity Map Analysis

    3.4. Investment Feasibility Matrix

    3.5. PESTLE and Porter’s Analysis

    3.6. Regulatory Landscape

        3.6.1. By Key Regions

        3.6.2. By Key Countries

    3.7. Regional Parent Market Outlook

4. Global Cytogenetic Systems Market Analysis 2017-2021 and Forecast, 2022-2032

    4.1. Historical Market Size Value (US$ Mn) Analysis, 2017-2021

    4.2. Current and Future Market Size Value (US$ Mn) Projections, 2022-2032

        4.2.1. Y-o-Y Growth Trend Analysis

        4.2.2. Absolute $ Opportunity Analysis

5. Global Cytogenetic Systems Market Analysis 2017-2021 and Forecast 2022-2032, By Technology

    5.1. Introduction / Key Findings

    5.2. Historical Market Size Value (US$ Mn) Analysis By Technology, 2017-2021

    5.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By Technology, 2022-2032

        5.3.1. Flow Cytometry

        5.3.2. Fluorescence In Situ Hybridization (FISH)

        5.3.3. Multiplex- Fluorescence In Situ Hybridization (M-FISH)

        5.3.4. Comparative Genomic Hybridization (CGH)

    5.4. Y-o-Y Growth Trend Analysis By Technology, 2017-2021

    5.5. Absolute $ Opportunity Analysis By Technology, 2022-2032

6. Global Cytogenetic Systems Market Analysis 2017-2021 and Forecast 2022-2032, By Application

    6.1. Introduction / Key Findings

    6.2. Historical Market Size Value (US$ Mn) Analysis By Application, 2017-2021

    6.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By Application, 2022-2032

        6.3.1. Genetic Disorders

        6.3.2. Neoplastic Diseases

        6.3.3. Personalized Medicine

        6.3.4. Others

    6.4. Y-o-Y Growth Trend Analysis By Application, 2017-2021

    6.5. Absolute $ Opportunity Analysis By Application, 2022-2032

7. Global Cytogenetic Systems Market Analysis 2017-2021 and Forecast 2022-2032, By End User

    7.1. Introduction / Key Findings

    7.2. Historical Market Size Value (US$ Mn) Analysis By End User, 2017-2021

    7.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By End User, 2022-2032

        7.3.1. Hospitals

        7.3.2. Clinics

        7.3.3. Diagnostic Laboratory Centers

        7.3.4. Research Institutes

    7.4. Y-o-Y Growth Trend Analysis By End User, 2017-2021

    7.5. Absolute $ Opportunity Analysis By End User, 2022-2032

8. Global Cytogenetic Systems Market Analysis 2017-2021 and Forecast 2022-2032, By Region

    8.1. Introduction

    8.2. Historical Market Size Value (US$ Mn) Analysis By Region, 2017-2021

    8.3. Current Market Size Value (US$ Mn) Analysis and Forecast By Region, 2022-2032

        8.3.1. North America

        8.3.2. Latin America

        8.3.3. Europe

        8.3.4. Asia Pacific

        8.3.5. MEA

    8.4. Market Attractiveness Analysis By Region

9. North America Cytogenetic Systems Market Analysis 2017-2021 and Forecast 2022-2032, By Country

    9.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021

    9.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032

        9.2.1. By Country

            9.2.1.1. US

            9.2.1.2. Canada

        9.2.2. By Technology

        9.2.3. By Application

        9.2.4. By End User

    9.3. Market Attractiveness Analysis

        9.3.1. By Country

        9.3.2. By Technology

        9.3.3. By Application

        9.3.4. By End User

    9.4. Key Takeaways

10. Latin America Cytogenetic Systems Market Analysis 2017-2021 and Forecast 2022-2032, By Country

    10.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021

    10.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032

        10.2.1. By Country

            10.2.1.1. Brazil

            10.2.1.2. Mexico

            10.2.1.3. Rest of Latin America

        10.2.2. By Technology

        10.2.3. By Application

        10.2.4. By End User

    10.3. Market Attractiveness Analysis

        10.3.1. By Country

        10.3.2. By Technology

        10.3.3. By Application

        10.3.4. By End User

    10.4. Key Takeaways

11. Europe Cytogenetic Systems Market Analysis 2017-2021 and Forecast 2022-2032, By Country

    11.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021

    11.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032

        11.2.1. By Country

            11.2.1.1. Germany

            11.2.1.2. U.K.

            11.2.1.3. France

            11.2.1.4. Spain

            11.2.1.5. Italy

            11.2.1.6. Rest of Europe

        11.2.2. By Technology

        11.2.3. By Application

        11.2.4. By End User

    11.3. Market Attractiveness Analysis

        11.3.1. By Country

        11.3.2. By Technology

        11.3.3. By Application

        11.3.4. By End User

    11.4. Key Takeaways

12. Asia Pacific Cytogenetic Systems Market Analysis 2017-2021 and Forecast 2022-2032, By Country

    12.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021

    12.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032

        12.2.1. By Country

            12.2.1.1. China

            12.2.1.2. Japan

            12.2.1.3. South Korea

            12.2.1.4. Rest of Asia Pacific

        12.2.2. By Technology

        12.2.3. By Application

        12.2.4. By End User

    12.3. Market Attractiveness Analysis

        12.3.1. By Country

        12.3.2. By Technology

        12.3.3. By Application

        12.3.4. By End User

    12.4. Key Takeaways

13. MEA Cytogenetic Systems Market Analysis 2017-2021 and Forecast 2022-2032, By Country

    13.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021

    13.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032

        13.2.1. By Country

            13.2.1.1. GCC Countries

            13.2.1.2. South Africa

            13.2.1.3. Israel

            13.2.1.4. Rest of MEA

        13.2.2. By Technology

        13.2.3. By Application

        13.2.4. By End User

    13.3. Market Attractiveness Analysis

        13.3.1. By Country

        13.3.2. By Technology

        13.3.3. By Application

        13.3.4. By End User

    13.4. Key Takeaways

14. Key Countries Cytogenetic Systems Market Analysis

    14.1. US

        14.1.1. Pricing Analysis

        14.1.2. Market Share Analysis, 2021

            14.1.2.1. By Technology

            14.1.2.2. By Application

            14.1.2.3. By End User

    14.2. Canada

        14.2.1. Pricing Analysis

        14.2.2. Market Share Analysis, 2021

            14.2.2.1. By Technology

            14.2.2.2. By Application

            14.2.2.3. By End User

    14.3. Brazil

        14.3.1. Pricing Analysis

        14.3.2. Market Share Analysis, 2021

            14.3.2.1. By Technology

            14.3.2.2. By Application

            14.3.2.3. By End User

    14.4. Mexico

        14.4.1. Pricing Analysis

        14.4.2. Market Share Analysis, 2021

            14.4.2.1. By Technology

            14.4.2.2. By Application

            14.4.2.3. By End User

    14.5. Germany

        14.5.1. Pricing Analysis

        14.5.2. Market Share Analysis, 2021

            14.5.2.1. By Technology

            14.5.2.2. By Application

            14.5.2.3. By End User

    14.6. U.K.

        14.6.1. Pricing Analysis

        14.6.2. Market Share Analysis, 2021

            14.6.2.1. By Technology

            14.6.2.2. By Application

            14.6.2.3. By End User

    14.7. France

        14.7.1. Pricing Analysis

        14.7.2. Market Share Analysis, 2021

            14.7.2.1. By Technology

            14.7.2.2. By Application

            14.7.2.3. By End User

    14.8. Spain

        14.8.1. Pricing Analysis

        14.8.2. Market Share Analysis, 2021

            14.8.2.1. By Technology

            14.8.2.2. By Application

            14.8.2.3. By End User

    14.9. Italy

        14.9.1. Pricing Analysis

        14.9.2. Market Share Analysis, 2021

            14.9.2.1. By Technology

            14.9.2.2. By Application

            14.9.2.3. By End User

    14.10. China

        14.10.1. Pricing Analysis

        14.10.2. Market Share Analysis, 2021

            14.10.2.1. By Technology

            14.10.2.2. By Application

            14.10.2.3. By End User

    14.11. Japan

        14.11.1. Pricing Analysis

        14.11.2. Market Share Analysis, 2021

            14.11.2.1. By Technology

            14.11.2.2. By Application

            14.11.2.3. By End User

    14.12. South Korea

        14.12.1. Pricing Analysis

        14.12.2. Market Share Analysis, 2021

            14.12.2.1. By Technology

            14.12.2.2. By Application

            14.12.2.3. By End User

    14.13. GCC Countries

        14.13.1. Pricing Analysis

        14.13.2. Market Share Analysis, 2021

            14.13.2.1. By Technology

            14.13.2.2. By Application

            14.13.2.3. By End User

    14.14. South Africa

        14.14.1. Pricing Analysis

        14.14.2. Market Share Analysis, 2021

            14.14.2.1. By Technology

            14.14.2.2. By Application

            14.14.2.3. By End User

    14.15. Israel

        14.15.1. Pricing Analysis

        14.15.2. Market Share Analysis, 2021

            14.15.2.1. By Technology

            14.15.2.2. By Application

            14.15.2.3. By End User

15. Market Structure Analysis

    15.1. Competition Dashboard

    15.2. Competition Benchmarking

    15.3. Market Share Analysis of Top Players

        15.3.1. By Regional

        15.3.2. By Technology

        15.3.3. By Application

        15.3.4. By End User

16. Competition Analysis

    16.1. Competition Deep Dive

        16.1.1. ADS Biotec Inc.

            16.1.1.1. Overview

            16.1.1.2. Product Portfolio

            16.1.1.3. Profitability by Market Segments

            16.1.1.4. Sales Footprint

            16.1.1.5. Strategy Overview

                16.1.1.5.1. Marketing Strategy

        16.1.2. Harris Computer Systems

            16.1.2.1. Overview

            16.1.2.2. Product Portfolio

            16.1.2.3. Profitability by Market Segments

            16.1.2.4. Sales Footprint

            16.1.2.5. Strategy Overview

                16.1.2.5.1. Marketing Strategy

        16.1.3. Laboratory Imaging s.r.o.

            16.1.3.1. Overview

            16.1.3.2. Product Portfolio

            16.1.3.3. Profitability by Market Segments

            16.1.3.4. Sales Footprint

            16.1.3.5. Strategy Overview

                16.1.3.5.1. Marketing Strategy

        16.1.4. MetaSystems

            16.1.4.1. Overview

            16.1.4.2. Product Portfolio

            16.1.4.3. Profitability by Market Segments

            16.1.4.4. Sales Footprint

            16.1.4.5. Strategy Overview

                16.1.4.5.1. Marketing Strategy

        16.1.5. Agilent Technologies

            16.1.5.1. Overview

            16.1.5.2. Product Portfolio

            16.1.5.3. Profitability by Market Segments

            16.1.5.4. Sales Footprint

            16.1.5.5. Strategy Overview

                16.1.5.5.1. Marketing Strategy

        16.1.6. OGT Ltd

            16.1.6.1. Overview

            16.1.6.2. Product Portfolio

            16.1.6.3. Profitability by Market Segments

            16.1.6.4. Sales Footprint

            16.1.6.5. Strategy Overview

                16.1.6.5.1. Marketing Strategy

        16.1.7. Leica Biosystems Nussloch GmbH

            16.1.7.1. Overview

            16.1.7.2. Product Portfolio

            16.1.7.3. Profitability by Market Segments

            16.1.7.4. Sales Footprint

            16.1.7.5. Strategy Overview

                16.1.7.5.1. Marketing Strategy

        16.1.8. Applied Spectral Imaging

            16.1.8.1. Overview

            16.1.8.2. Product Portfolio

            16.1.8.3. Profitability by Market Segments

            16.1.8.4. Sales Footprint

            16.1.8.5. Strategy Overview

                16.1.8.5.1. Marketing Strategy

        16.1.9. Irvine Scientific

            16.1.9.1. Overview

            16.1.9.2. Product Portfolio

            16.1.9.3. Profitability by Market Segments

            16.1.9.4. Sales Footprint

            16.1.9.5. Strategy Overview

                16.1.9.5.1. Marketing Strategy

        16.1.10. PerkinElmer Inc.

            16.1.10.1. Overview

            16.1.10.2. Product Portfolio

            16.1.10.3. Profitability by Market Segments

            16.1.10.4. Sales Footprint

            16.1.10.5. Strategy Overview

                16.1.10.5.1. Marketing Strategy

        16.1.11. Bio-Rad Laboratories

            16.1.11.1. Overview

            16.1.11.2. Product Portfolio

            16.1.11.3. Profitability by Market Segments

            16.1.11.4. Sales Footprint

            16.1.11.5. Strategy Overview

                16.1.11.5.1. Marketing Strategy

        16.1.12. Abbott Laboratories

            16.1.12.1. Overview

            16.1.12.2. Product Portfolio

            16.1.12.3. Profitability by Market Segments

            16.1.12.4. Sales Footprint

            16.1.12.5. Strategy Overview

                16.1.12.5.1. Marketing Strategy

17. Assumptions & Acronyms Used

18. Research Methodology

Recommendations

Healthcare

Cytotoxic Drugs Market

December 2022

REP-GB-2515

322 pages

Healthcare

Molecular Cytogenetics Market

October 2022

REP-GB-2031

300 pages

Healthcare

Cytotoxicity Assays Market

March 2022

REP-GB-10024

250 pages

Explore Healthcare Insights

View Reports
Future Market Insights

Cytogenetic Systems Market

Schedule a Call